Genitourinary Cancers

A new German multicenter study is suggesting that lutetium-177 (Lu-177)-labeled PSMA-617 may be a promising new therapeutic agent for radioligand therapy in men with metastatic castration-resistant prostate cancer.

In patients with upper tract urothelial carcinoma, adjuvant chemotherapy following radical nephroureterectomy confers a survival advantage compared with observation following radical nephroureterectomy.

A new study is suggesting it may be possible to shut down the circuits that drive the high tumorigenicity of prostate cancer cells leading to castration-resistant prostate cancer.

An early study looking at the combination of the ALK1 inhibitor dalantercept plus axitinib showed clinical activity in patients with advanced renal cell carcinoma.

The FDA has concluded that pioglitazone, used to treat type 2 diabetes, may be linked to an increased risk of bladder cancer.

An increasing percentage of men over the age of 75 who are diagnosed with prostate cancer have distant metastases at the time of diagnosis, according to a new study.

Although the use of sorafenib in patients with treatment-naive metastatic renal cell carcinoma demonstrated clinical benefit, a phase IIb study did not support the use of dose escalation in these patients.

Vascular-targeted photodynamic therapy with padeliporfin was significantly better than active surveillance over a 2-year period in men with low-risk localized prostate cancer.

The US Food and Drug Administration has accepted the first Biologics License Application for durvalumab (MEDI4736) to treat patients with urothelial cancer (UC) for whom cisplatin failed to stop disease progression.

Investigators at the Dana-Farber Cancer Institute in Boston for the first time have identified unique genomic changes that may be integral to testicular cancer.

Researchers from X4 Pharmaceuticals in Cambridge, Mass., have been developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the ability for T cells to track and destroy cancer.

Long-term follow-up showed no reduction in prostate cancer mortality with yearly prostate-specific antigen testing.

The combination of CB-839, a selective inhibitor of glutaminase, and everolimus seems to have disease activity in patients with advanced renal cell carcinoma.

Patients with metastatic renal cell carcinoma treated with sunitinib often experience treatment-related hypertension and require rigorous blood pressure control.

The use of radiotherapy was associated with an overall survival benefit in patients with prostate cancer and lymph node involvement who underwent radical prostatectomy and were also treated with androgen-deprivation therapy.

Metastatic renal cell carcinoma (mRCC) patients who use non-aspirin NSAIDs have poorer overall survival than aspirin users and NSAID non-users, according to a new pooled retrospective analysis.

A recent study published in European Urology suggests that patterns of treatment failure might help to predict what the next treatment should be for patients with metastatic renal cell carcinoma.

Medical researchers at Indiana University Bloomington are reporting that prostate cancer may be much more closely related to Ewing’s sarcoma than previously recognized.

With a number of therapies now available for treatment of renal cell carcinoma, research is now ongoing to determine the best possible sequencing and potential combinations of those therapies.

The use of proton pump inhibitors does not appear to impact the efficacy of oral VEGF tyrosine kinase inhibitors in metastatic renal cell carcinoma, according to a new study.

The use of immune checkpoint inhibitors as adjuvant or neoadjuvant therapy in kidney cancer could offer important new treatment options. Questions remain, though, on the timing and sequence of therapy.

Specific tumor genotypes could represent distinct subtypes of clear cell renal cell carcinoma, according to a new analysis of the RECORD-3 trial. Genotyping could potentially help guide treatment decisions if the results can be validated.

A small study found that patients with metastatic renal cell carcinoma (mRCC) who discontinue nivolumab due to immune-related adverse events can continue to derive benefit even after cessation of therapy.

The combination of bevacizumab and an investigational nanoparticle-drug conjugate known as CRLX101 failed to improve outcomes in metastatic renal cell carcinoma compared with standard of care.

A phase III study of adjuvant girentuximab in patients with high-risk clear cell RCC showed that the drug provided no clinical benefit compared with placebo.